Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells

Kruppel-like factor 6 (KLF6) is a member of the family of Kruppel transcription factors, this plays an important role in the regulation of cell growth, differentiation and angiogenesis. Rosiglitazone is a PPARy agonist drug, its antitumor effect has been described in models of breast and colon cance...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rojas,Víctor, Laime,Delia
Lenguaje:	English
Publicado:	Sociedad Chilena de Anatomía 2017
Materias:	KLF6 Rosiglitazone Colon and KLF6 Colon
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022017000100042
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0717-95022017000100042
record_format	dspace
spelling	oai:scielo:S0717-950220170001000422017-04-18Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer CellsRojas,VíctorLaime,Delia KLF6 Rosiglitazone Colon and KLF6 KLF6 Rosiglitazone Colon KLF6 Kruppel-like factor 6 (KLF6) is a member of the family of Kruppel transcription factors, this plays an important role in the regulation of cell growth, differentiation and angiogenesis. Rosiglitazone is a PPARy agonist drug, its antitumor effect has been described in models of breast and colon cancer. The aim of this study is to evaluate the level of expression of KLF6 in Caco2 cells treated with Avandia. For this a Immunofluorescence was performed, the Caco2 cells were cultured and treated with Rosiglitazone, another group was treated with Rosiglitazone and GW-9662, inhibitor for Immunofluorescence an anti-KLF6 antibody and a secondary antibody coupled to Alexa-488 was used . Cells were observed in a fluorescence microscope and images were processed. The results show that KLF6 is expressed in the cytoplasm of cells Caco2. Compared to treatment with Avandia, KLF6 increases its expression in the cytoplasm. When cells were treated with GW-9662 inhibitor, an expression of KLF6 in the nucleus was observed. KLF6 expression in the cytoplasm of cells Caco2, could be explained by the knowledge of splicing variants SV1 and SV2, these abnormally accumulate in the cytoplasm and promotes cell growth. It is concluded that in untreated Caco 2 cells, KLF6 is expressed in the cytoplasm. Compared to treatment with Rosiglitazone, KLF6 upregulated in the cytoplasm and compared to treatment with the inhibitor, KLF6 is expressed in the nucleus of Caco 2 cells.info:eu-repo/semantics/openAccessSociedad Chilena de AnatomíaInternational Journal of Morphology v.35 n.1 20172017-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022017000100042en10.4067/S0717-95022017000100042
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	KLF6 Rosiglitazone Colon and KLF6 KLF6 Rosiglitazone Colon KLF6
spellingShingle	KLF6 Rosiglitazone Colon and KLF6 KLF6 Rosiglitazone Colon KLF6 Rojas,Víctor Laime,Delia Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells
description	Kruppel-like factor 6 (KLF6) is a member of the family of Kruppel transcription factors, this plays an important role in the regulation of cell growth, differentiation and angiogenesis. Rosiglitazone is a PPARy agonist drug, its antitumor effect has been described in models of breast and colon cancer. The aim of this study is to evaluate the level of expression of KLF6 in Caco2 cells treated with Avandia. For this a Immunofluorescence was performed, the Caco2 cells were cultured and treated with Rosiglitazone, another group was treated with Rosiglitazone and GW-9662, inhibitor for Immunofluorescence an anti-KLF6 antibody and a secondary antibody coupled to Alexa-488 was used . Cells were observed in a fluorescence microscope and images were processed. The results show that KLF6 is expressed in the cytoplasm of cells Caco2. Compared to treatment with Avandia, KLF6 increases its expression in the cytoplasm. When cells were treated with GW-9662 inhibitor, an expression of KLF6 in the nucleus was observed. KLF6 expression in the cytoplasm of cells Caco2, could be explained by the knowledge of splicing variants SV1 and SV2, these abnormally accumulate in the cytoplasm and promotes cell growth. It is concluded that in untreated Caco 2 cells, KLF6 is expressed in the cytoplasm. Compared to treatment with Rosiglitazone, KLF6 upregulated in the cytoplasm and compared to treatment with the inhibitor, KLF6 is expressed in the nucleus of Caco 2 cells.
author	Rojas,Víctor Laime,Delia
author_facet	Rojas,Víctor Laime,Delia
author_sort	Rojas,Víctor
title	Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells
title_short	Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells
title_full	Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells
title_fullStr	Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells
title_full_unstemmed	Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells
title_sort	rosiglitazone role in the expression of klf6 caco-2 colon cancer cells
publisher	Sociedad Chilena de Anatomía
publishDate	2017
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022017000100042
work_keys_str_mv	AT rojasvictor rosiglitazoneroleintheexpressionofklf6caco2coloncancercells AT laimedelia rosiglitazoneroleintheexpressionofklf6caco2coloncancercells
_version_	1718444995069870080

Rosiglitazone Role in the Expression of KLF6 Caco-2 Colon Cancer Cells

Ejemplares similares